Remaining Steadfast: Goodwin’s Life Sciences in 2023

Amid the dynamic shifts of macroeconomic and financings trends of 2023, the life sciences industry found itself navigating rough waters. Despite challenges, it demonstrated unwavering resilience in its pursuit of discovery and innovation.

This annual recap highlights Goodwin’s continued determination and agility as a full-service, integrated global practice. Committed to being a global destination life cycle law firm to the life sciences industry, we are proud to stand alongside and counsel leading life sciences companies driving transformative innovation. Our ongoing client partnerships inspire us; we look forward to navigating the evolving life sciences landscape together in 2024 and beyond.

By The Numbers

Financing (VC) transactions for $8 Billion+
Collaboration transactions for $5.9 Billion+
M&A transactions for $10 Billion+
Equity offerings (including initial public offerings and follow-on offerings) for $7.9 Billion+
(Representation of both issuers and underwriters)

Global Market Recognition

Notable Deals

Globus Medical

Counsel to Globus Medical on its $3.1 billion definitive agreement to combine with NuVasive in an all-stock transaction.

Royalty Pharma

Counsel to Royalty Pharma in its agreement with PTC Therapeutics to acquire additional royalties on Roche’s Evrysdi for up to $1.5 billion.


Counsel to Versanis Bio in its $1.925 billion definitive agreement to be acquired by Eli Lilly and Company.


Counsel to ElevateBio in its $401 million Series D financing.

Teva Pharmaceuticals

Counsel to Teva Pharmaceuticals on its $1 billion collaboration with Sanofi.


Counsel to Seagen on its $3.4 billion multi-target strategic collaboration agreement with Nurix Therapeutics.


Counsel to Mablink Bioscience in its agreement to be acquired by Eli Lilly and Company.